Silence Therapeutics has received a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and started a new cross-border interim injunction application in the Netherlands against Alnylam's Onpattro (patisiran).
AIDS Healthcare Foundation (AHF) has filed a petition for writ of certiorari (a petition for review) with the Supreme Court of the US, seeking the Court’s review of the dismissal of a federal lawsuit filed by AHF in January 2016 against Gilead Sciences and other defendants alleging its patent for a key HIV/AIDS drug, tenofovir alafenamide (TAF) is invalid because Gilead manipulated the patent system.
AstraZeneca has agreed to pay $110m to settle Texas drugs lawsuit claims of fraudulently marketing Seroquel and Crestor.
A US court has approved Indivior’s preliminary injunction (PI) preventing Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.
Alnylam Pharmaceuticals has entered into a settlement agreement with Dicerna Pharmaceuticals to resolve trade secret misappropriation claims against Dicerna, and counterclaims asserted by Dicerna, in pending litigation in the Superior Court of Middlesex County, Massachusetts.
Endo International has won a preliminary injunction in the US, barring QuVa Pharm from introducing a compounding drug that could compete with its Vasostrict, the vasopressin injection indicated to increase blood pressure in adults with vasodilatory shock.
The UK Competition and Markets Authority (CMA) has accused Canadian pharma company Concordia International of abusing its dominant position by increasing the price of a thyroid drug by about 6,000%.
Pharmaceutical companies Concordia International and Actavis UK have been alleged of illegally colluding to keep prices of hydrocortisone tablets high in the UK.
US-based Biogen has agreed to pay Danish firm Forward Pharma $1.25bn to resolve a dispute over a patent on multiple sclerosis drug.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.